Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

Key Points

• Zentalis Pharmaceuticals reported a quarterly loss of $0.59 per share, missing the consensus estimate of a $0.45 loss by $0.14.
• The stock traded around $5.00, with shares up slightly; analysts’ average rating is “Hold,” with an average price target of $6.75, though individual targets range as high as $11.00.
• The clinical-stage biotechnology company is developing oncology treatments, including its lead candidate ZN-c3, an oral p53-MDM2 inhibitor in Phase I trials for advanced cancers.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.14), FiscalAI reports.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock traded up $0.05 during trading on Thursday, hitting $5.00. The stock had a trading volume of 701,420 shares, compared to its average volume of 1,656,577. The firm's fifty day simple moving average is $4.29 and its 200-day simple moving average is $3.58. The stock has a market cap of $355.93 million, a PE ratio of -2.89 and a beta of 1.92. Zentalis Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $6.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a "buy" rating and a $11.00 price target on the stock. Guggenheim increased their target price on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, April 10th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Finally, Mizuho assumed coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an "outperform" rating and a $8.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $6.75.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZNTL. Qube Research & Technologies Ltd purchased a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $37,000. Voleon Capital Management LP purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at $41,000. Algert Global LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at $73,000. Corient Private Wealth LLC bought a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at $83,000. Finally, State of Wyoming increased its stake in Zentalis Pharmaceuticals by 63.4% in the second quarter. State of Wyoming now owns 73,797 shares of the company's stock worth $86,000 after purchasing an additional 28,621 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source